Protocols · MSK/Tissue Repair
BPC-157 Tendon & Ligament Repair Protocol
Body Protection Compound | Tendon & Ligament Repair
Typical Dose
250–500 mcg
per local injection site
Route
Local SC
Peri-tendinous / peri-lesional
Cycle
8–12 weeks
Loading → consolidation → taper
Storage
Refrigerate 2–8°C
After reconstitution; protect from light
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
This protocol targets connective tissue injury — chronic tendinopathy (Achilles, patellar, lateral/medial epicondylar, rotator cuff), acute and subacute ligamentous sprains (ATFL, MCL, UCL), and adjunctive support following surgical tendon repair or reconstruction (e.g., ACL allograft, rotator cuff repair, Achilles primary repair). The clinical goal is to accelerate collagen organization, modulate the inflammatory phase of healing, and restore tensile load capacity in tissues with notoriously poor vascular supply.
The target patient is one who has failed or plateaued on conservative measures (relative rest, eccentric loading, NSAID trials, PT) or is in a defined post-operative window where biologic augmentation may shorten the rehab arc. BPC-157 is used here as a monotherapy delivered locally — proximate or peri-lesional — to maximize tissue concentration at the site of injury while minimizing systemic exposure.
While BPC-157 is frequently stacked with TB-500/TB4-Frag or growth-hormone secretagogues for broader regenerative protocols, this document is intentionally narrow: a single-agent, injection-based regimen optimized for focal MSK repair. Stacking can be considered in a separate protocol if response is inadequate at 8 weeks.
Key Benefits
Accelerates collagen organization and angiogenesis at sites of poor vascular supply, shortening rehab arcs for chronic tendinopathy, ligament sprains, and post-surgical tendon repair.
Mechanism of Action
Upregulates VEGFR2-driven angiogenesis, activates FAK-paxillin signaling for tenocyte migration, and sensitizes tendon fibroblasts to growth hormone — favoring organized type I collagen deposition.
Molecular Information
Weight
1419.5 Da
Length
15 amino acids
Type
Synthetic pentadecapeptide (gastric juice derivative)
Amino Acid Sequence
GEPPPGKPADDAGLV
* Stable in human gastric juice; synthetic form derived from a fragment of body protection compound isolated from gastric secretions.
Pharmacokinetics
Peak
~15–30 min (systemic)
Half-life
<30 min plasma (rodent)
Cleared
Local tissue effects outlast systemic clearance
Research Indications
Chronic TendinopathyEMERGING
Achilles / Patellar
Targets watershed hypovascular zones; VISA-A/P improvements of 15–25 points in responders by week 8.
Epicondylar (lateral/medial)
Peri-lesional injection improves tolerance to loading before resting pain change.
Rotator Cuff
Supraspinatus critical-zone perfusion benefit; pair with progressive loading.
Ligament SprainEMERGING
ATFL / MCL / UCL
Acute and subacute grade I–II injury; supports collagen organization during proliferative phase.
Mechanotransduction Pairing
Timed with isometric then heavy-slow resistance to drive aligned fiber remodeling.
Post-Surgical RepairEMERGING
ACL allograft / Rotator cuff / Achilles primary repair
Begin ≥7–10 days post-op with surgeon clearance; peri-incisional 250 mcg every other day.
Rehab Acceleration
Adjunct to standard post-op loading protocols, not a replacement.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Loading (Weeks 1–2) | 250–500 mcg | Daily | Local SC / peri-lesional |
| Large structure (Achilles, quad, supraspinatus) | 250 mcg x 2 sites | Daily | Local SC, split sites |
| Consolidation (Weeks 3–6) | 250–500 mcg | Every other day (M/W/F) | Local SC |
| Taper (Weeks 7–12) | 250 mcg | 2–3x weekly | Local SC |
| Post-surgical (start day 7–10) | 250 mcg | Every other day x 4 weeks, then 2x weekly | Peri-incisional / peri-graft SC |
Timing · Inject as close to the lesion as anatomy permits using a 27–30G insulin syringe. Pair pharmacology with progressive loading — isometric in week 1, transitioning to heavy-slow resistance or eccentric work. Avoid concomitant NSAIDs and same-site corticosteroid injection within 4–6 weeks.
Peptide Interactions
- TB-500 / TB4-Frag— Common stack for broader regenerative protocols; consider if monotherapy plateaus at 8 weeks.SYNERGISTIC
- CJC-1295 / Ipamorelin— GH axis support amplifies fibroblast GH-receptor signaling for collagen remodeling.SYNERGISTIC
- GHK-Cu— Complementary remodeling and ECM signaling; safe to co-administer.SYNERGISTIC
- IGF-1 LR3— Local anabolic potential but tendon-specific data sparse; avoid in active malignancy.MONITOR
- Corticosteroid injection (same site)— Blunts reparative signaling; avoid within 4–6 weeks of protocol.AVOID
- Chronic NSAIDs— Impairs tendon-to-bone healing and antagonizes reparative inflammatory cascade.AVOID
How to Reconstitute
- 1
Wash hands and clean the work surface with 70% isopropyl alcohol.
- 2
Allow the 10 mg lyophilized BPC-157 vial to reach room temperature (5–10 min).
- 3
Wipe both vial stoppers (peptide and bacteriostatic water) with alcohol swabs.
- 4
Draw 2.0 mL of bacteriostatic water into a 3 mL syringe.
- 5
Insert the needle into the BPC-157 vial at a 45° angle and let the diluent drip slowly down the inner wall — do not jet directly onto the powder.
- 6
Remove the syringe and gently swirl the vial until fully dissolved. Do not shake.
- 7
Final concentration: 5 mg/mL — 0.05 mL = 250 mcg, 0.10 mL = 500 mcg on a U-100 insulin syringe.
- 8
Label the vial with reconstitution date and concentration.
- 9
Store refrigerated at 2–8°C; protect from light.
- 10
Draw the prescribed dose into a 27–30G insulin syringe; expel any air.
- 11
Clean the injection site with alcohol and allow to dry; inject SC peri-lesionally or into the peri-tendinous space.
- 12
Discard the syringe in a sharps container. Use the vial within 30 days of reconstitution.
Quality Indicators
Lyophilized white powder
Cake should be intact or finely powdered, no discoloration.
Clear solution after reconstitution
Fully dissolved within 30–60 seconds of gentle swirling, no particulates.
Cloudy or particulate solution
Indicates degradation or contamination — discard.
Yellow tint or visible debris
Do not use; obtain replacement vial from a reputable compounder.
What to Expect
Week 1–2: transient injection-site soreness, mild erythema or bruising is common.
Week 4: 20–40% VAS reduction in resting and palpation pain in typical responders.
Patients often notice improved load tolerance before resting pain changes.
Week 8: functional gains — single-leg hop, grip, sport-specific provocation testing improve.
Ultrasound at week 8–12 may show reduced hypoechoic lesion size and Doppler neovascularity.
VISA-A/P scores typically improve 15–25 points in responders.
Week 12: maximal protocol benefit; responders near or at pre-injury function with loading.
Non-responders identifiable by week 8 — consider re-imaging and PRP / surgical consult.
Diabetics, smokers, and chronic steroid users tend to underperform.
Pharmacology without progressive loading produces disorganized scar — adherence to rehab is essential.
Side Effects & Safety
- Injection-site erythema, bruising, or soreness (most common)
- Transient lightheadedness or flushing post-injection (uncommon)
- Mild nausea or fatigue (rare, more with systemic dosing)
- Theoretical angiogenic concern in active malignancy or proliferative retinopathy
- No well-characterized systemic adverse events at protocol doses
- No known drug-drug interactions of clinical significance
When to Stop & Call Provider
- Visual changes or new floaters (concern for neovascular retinopathy)
- Signs of injection-site infection: spreading erythema, warmth, purulent drainage, fever
- Allergic reaction: hives, swelling, dyspnea, anaphylaxis
- New unexplained mass, lymphadenopathy, or systemic symptoms suggestive of malignancy
- Thromboembolic event or signs of DVT/PE
References
Chang et al. — BPC-157 and tendon fibroblast outgrowth (growth hormone receptor pathway)
Demonstrated BPC-157 upregulates growth hormone receptor expression on tendon fibroblasts, supporting proliferation and collagen synthesis during the remodeling phase.
Krivic et al. — BPC-157 and Achilles tendon-to-bone healing
Accelerated tendon-to-bone reattachment with improved biomechanical load-to-failure following Achilles detachment and BPC-157 administration.
Staresinic et al. — BPC-157 in transected Achilles tendon
Improved functional recovery and histologic organization of healing tendon in transection model versus saline controls.
Pevec et al. — BPC-157 in MCL injury
Faster functional recovery and improved biomechanical properties of healing MCL with peri-lesional BPC-157.
Hsieh et al. — VEGFR2 / eNOS angiogenic axis with BPC-157
Characterizes VEGFR2 upregulation and downstream eNOS-NO signaling as a primary mechanism for BPC-157's pro-angiogenic effects in injured tissue.